Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 26 (5), 567-70

Improved Bioavailability of a Micronized Megestrol Acetate Tablet Formulation in Humans

Affiliations

Improved Bioavailability of a Micronized Megestrol Acetate Tablet Formulation in Humans

A Farinha et al. Drug Dev Ind Pharm.

Abstract

Megestrol acetate, a progestogen widely used in the palliative treatment of endometrial carcinoma and breast cancer, is currently administered orally as a solid dosage form. Bioavailability of the drug following oral administration is closely related to the effectiveness and safety profile of the drug in formulation. Improved immediate-release formulations should allow improved drug delivery into the systemic circulation and, at the end, to the site of action. The micronization of drugs is one of the technological procedures to achieve such a purpose. This paper reports the design and results obtained in an in vivo study of the bioavailability of a micronized megestrol acetate tablet formulation compared to a conventional form. A significant increase in the drug bioavailability was observed, in either the rate or the extent of absorption. In vitro dissolution data of the two study formulations reflected the in vivo findings.

Similar articles

See all similar articles

Cited by 6 PubMed Central articles

See all "Cited by" articles

LinkOut - more resources

Feedback